These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 32975679)

  • 1. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
    Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Chehrehgosha H; Sohrabi MR; Ismail-Beigi F; Malek M; Reza Babaei M; Zamani F; Ajdarkosh H; Khoonsari M; Fallah AE; Khamseh ME
    Diabetes Ther; 2021 Mar; 12(3):843-861. PubMed ID: 33586120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.
    Attaran F; Emami S; Sohrabi M; Malek M; Ajdarkosh H; Khoonsari M; Ismail-Beigi F; Khamseh ME
    BMC Gastroenterol; 2023 Sep; 23(1):327. PubMed ID: 37742004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
    Kahl S; Ofstad AP; Zinman B; Wanner C; Schüler E; Sattar N; Inzucchi SE; Roden M
    Diabetes Obes Metab; 2022 Jun; 24(6):1061-1071. PubMed ID: 35166009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Cheung KS; Ng HY; Hui RWH; Lam LK; Mak LY; Ho YC; Tan JT; Chan EW; Seto WK; Yuen MF; Leung WK
    Hepatology; 2024 Oct; 80(4):916-927. PubMed ID: 38536017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.
    Lukenda Zanko V; Domislovic V; Trkulja V; Krznaric-Zrnic I; Turk-Wensveen T; Krznaric Z; Filipec Kanizaj T; Radic-Kristo D; Bilic-Zulle L; Orlic L; Dinjar-Kujundzic P; Poropat G; Stimac D; Hauser G; Mikolasevic I
    Diabetes Obes Metab; 2020 Nov; 22(11):2097-2106. PubMed ID: 32613718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Tang X; Zhang H; Wang X; Yang D
    Afr Health Sci; 2022 Sep; 22(3):391-398. PubMed ID: 36910362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes.
    Nobarani S; Alaei-Shahmiri F; Aghili R; Malek M; Poustchi H; Lahouti M; Khamseh ME
    Dig Dis Sci; 2022 Apr; 67(4):1389-1398. PubMed ID: 33788095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
    Lavynenko O; Abdul-Ghani M; Alatrach M; Puckett C; Adams J; Abdelgani S; Alkhouri N; Triplitt C; Clarke GD; Vasquez JA; Li J; Cersosimo E; Gastaldelli A; DeFronzo RA
    Diabetes Obes Metab; 2022 May; 24(5):899-907. PubMed ID: 35014145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: A randomized, placebo-controlled trial.
    Leite NC; Viegas BB; Villela-Nogueira CA; Carlos FO; Cardoso CRL; Salles GF
    Diabetes Obes Metab; 2019 May; 21(5):1266-1270. PubMed ID: 30687994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
    Sattar N; Fitchett D; Hantel S; George JT; Zinman B
    Diabetologia; 2018 Oct; 61(10):2155-2163. PubMed ID: 30066148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study.
    Hiruma S; Shigiyama F; Kumashiro N
    Diabetes Obes Metab; 2023 Jun; 25(6):1576-1588. PubMed ID: 36749298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.